Nonadherence to guidelines for prescribing antiplatelet/anticoagulant therapy in patients with atrial fibrillation

被引:6
|
作者
Navarro-Juan, Miguel [1 ]
Carbonell-Torregrosa, Maria A. [1 ]
Palazon-Bru, Antonio [2 ,3 ]
Martinez-Diaz, Ana M. [1 ]
Gil-Guillen, Vicente F. [2 ,3 ]
机构
[1] Elda Hosp, Emergency Unit, Alicante, Spain
[2] Miguel Hernandez Univ, Dept Clin Med, Alicante, Spain
[3] Elda Hosp, Res Unit, Alicante, Spain
关键词
Anticoagulants; atrial fibrillation; physician's practice patterns; platelet aggregation inhibitors; primary health care; EUROPEAN-SOCIETY; RISK-FACTORS; MANAGEMENT; STROKE; WARFARIN; HISTORY;
D O I
10.1093/fampra/cmw017
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. We have found no papers evaluating nonadherence to guidelines for the treatment of atrial fibrillation (AF), taking into account the two risk scales [C, congestive heart failure; H, hypertension; A, age; D, diabetes mellitus; S, stroke (CHADS(2)) and C, congestive heart failure; H, hypertension; A, age; D, diabetes mellitus; S, stroke; V, vascular disease; A, age; Sc, sex category (CHA(2)DS(2)-VASc)] and the two types of treatment that are recommended (antiplatelet/anticoagulant therapy). Objective. To determine the extent of lack of adherence when prescribing anticoagulant and antiplatelet therapy to patients with AF and associated factors. Methods. Cross-sectional, observational study of 144 patients with AF who visited the emergency department of Elda Hospital in 2013-14 (Spain). Main variable: the patient was prescribed a therapy different from that indicated by the guidelines (nonadherence) or not prescribed any therapy. Secondary variables: CHADS(2), CHA(2)DS(2)-VASc, HAS-BLED, type of AF and symptoms related to AF. Multivariate models were constructed to identify the associated factors by calculating the adjusted odds ratios (OR). Results. Nonadherence occurred in 90 patients [62.5%, 95% confidence interval (CI): 54.6-70.4%]. Associated factors were higher CHADS(2) (OR = 1.30, 95% CI: 0.96-1.75, P = 0.091) and CHA(2)DS(2)-VASc (OR = 1.23, 95% CI: 1.02-1.47, P = 0.027), and lower HAS-BLED (OR = 0.67, 95% CI: 0.49-0.91, P = 0.011). Conclusions. Nonadherence to guidelines was found in three out of every five patients. A greater cerebrovascular risk and a lower haemorrhagic risk were associated with this behaviour. Qualitative studies are needed to determine the causes.
引用
收藏
页码:290 / 295
页数:6
相关论文
共 50 条
  • [1] Combination Anticoagulant and Antiplatelet Therapy in Atrial Fibrillation Patients
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (09): : 972 - 975
  • [2] Reasons for not prescribing anticoagulant therapy in patients with stroke and atrial fibrillation
    Budincevic, H.
    Bielen, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 62 - 63
  • [3] Construction and validation of a model to predict nonadherence to guidelines for prescribing antiplatelet therapy to hypertensive patients
    Palazon-Bru, Antonio
    Jose Martinez-Orozco, Miguel
    Perseguer-Torregrosa, Zeneida
    Sepehri, Armina
    Manuel Folgado-de la Rosa, David
    Orozco-Beltran, Domingo
    Carratala-Munuera, Concepcion
    Francisco Gil-Guillen, Vicente
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (05) : 883 - 889
  • [4] Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention
    Woods, Erin A.
    Ackman, Margaret L.
    Graham, Michelle M.
    Koshman, Sheri L.
    Boswell, Rosaleen M.
    Barry, Arden R.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2016, 69 (04): : 280 - 285
  • [5] Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation
    Falk, RH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (08) : 1567 - 1569
  • [6] COMBINED ANTIPLATELET AND ANTICOAGULANT THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION-A DESCRIPTIVE STUDY
    So, Charlotte
    Eckman, Mark H.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 : S124 - S125
  • [7] Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Gott, Koji
    Nakai, Kentaro
    Shizuta, Satoshi
    Morimoto, Takeshi
    Shiomi, Hiroki
    Natsuaki, Masahiro
    Yahata, Mitsuhiko
    Ota, Chihiro
    Ono, Koh
    Makiyama, Takeru
    Nakagawa, Yoshihisa
    Furukawa, Yutaka
    Kadota, Kazushige
    Takatsu, Yoshiki
    Tamura, Takashi
    Takizawa, Akinori
    Inada, Tsukasa
    Doi, Osamu
    Nohara, Ryuji
    Matsuda, Mitsuo
    Takeda, Teruki
    Kato, Masayuki
    Shirotani, Manabu
    Eizawa, Hiroshi
    Ishii, Katsuhisa
    Lee, Jong-Dae
    Takahashi, Masaaki
    Horie, Minoru
    Takahashi, Mamoru
    Miki, Shinji
    Aoyama, Takeshi
    Suwa, Satoru
    Hamasaki, Shuichi
    Ogawa, Hisao
    Mitsudo, Kazuaki
    Nobuyoshi, Masakiyo
    Kita, Toru
    Kimura, Takeshi
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (01): : 70 - 78
  • [8] Additional Effects of Antiplatelet Therapy on Anticoagulant Agents in Patients With Bioprosthetic Valves and Atrial Fibrillation
    Amano, Masashi
    Miyake, Makoto
    Kitai, Takeshi
    Obayashi, Yuki
    Takegami, Misa
    Nishimura, Kunihiro
    Furukawa, Yutaka
    Izumi, Chisato
    CIRCULATION JOURNAL, 2022, 86 (03) : 415 - 424
  • [9] Prevention of stroke in patients with atrial fibrillation Anticoagulant and antiplatelet options
    Varughese, Christopher J.
    Halperin, Jonathan L.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2012, 35 (01) : 19 - 27
  • [10] Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation
    Thomson, R
    Parkin, D
    Eccles, M
    Sudlow, M
    Robinson, A
    LANCET, 2000, 355 (9208): : 956 - 962